Physician profile
Imdad Ahmad
NPI 1568499606
$1,732.00
in general payments reported to CMS, 2019-2025
26 companies · $23.65 in 2025
The $23.65 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.13 · 2022: $311 · 2023: $662 · 2024: $668 · 2025: $23.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $346.30 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $203.31 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $134.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.67 | 2022-2023 | Xifaxan |
| Sumitomo Pharma America, INC. | $106.08 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $99.03 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $74.87 | 2022-2023 | Prolia, Evenity, Otezla |
| Novartis Pharmaceuticals Corporation | $73.44 | 2024 | |
| Sanofi Pasteur INC. | $66.21 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $62.76 | 2023-2024 | Airsupra, Fasenra, Farxiga |
| Glaxosmithkline, LLC. | $59.48 | 2024 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $54.77 | 2024 | Voquezna |
| Tactile Systems Technology INC | $51.29 | 2024 | Flexitouch Plus, Entre Plus |
| Hologic Sales and Service, LLC | $47.27 | 2023-2025 | Thinprep 2000 Processor, Aptima |
| Otsuka America Pharmaceutical, INC. | $35.34 | 2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $24.61 | 2023 | |
| Biogen, INC. | $21.82 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.38 | 2022 | |
| Lundbeck LLC | $21.02 | 2023 | Rexulti |
| Acerus Pharmaceuticals Corporation | $20.56 | 2022 | |
| Merck Sharp & Dohme LLC | $19.10 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Almatica Pharma LLC | $15.87 | 2021 | |
| Grifols USA, LLC | $15.23 | 2023 | Prolastin-C Liquid |
| Esperion Therapeutics, INC. | $14.34 | 2023 | Nexletol |
| Novo Nordisk INC | $13.84 | 2023 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imdad Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.